Lintuzumab, a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest activity against acute myeloid leukemia (AML). To increase the antibody's potency yet avoid nonspecific cytotoxicity seen with -emitting isotopes, lintuzumab was conjugated to the -emitters bismuth-213 ( Ac-lintuzumab in a phase I study. Dose-limiting toxicities were myelosuppression lasting >35 days in one patient and death due to sepsis in two patients. The maximum tolerated dose (MTD) was 111 KBg/kg. Bone marrow blast reductions were seen across all dose levels. Targeted -particle immunotherapy with   213   Bi-and   225 Ac-lintuzumab is safe, has significant antileukemic effects, and can produce remissions after partial cytoreduction.
INTRODUCTION
Although standard induction therapy with cytarabine and an anthracycline produces complete remissions (CR) in 50 to 70% of patients with acute myeloid leukemia (AML), but long-term survival is seen in only 20 to 40% of patients. 1 Following relapse, salvage chemotherapy produces remissions in only 20 to 25% of patients. While allogeneic hematopoietic cell transplantation (HCT) can result in longterm survival in approximately 30% of patients with relapsed AML, most patients are not appropriate candidates due to age, comorbidities or lack of a suitable donor. 2 The prognosis for elderly patients is even worse with a 5-year survival rate of 5% for patients more than 65 years of age. 3 
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Therefore, new therapies are needed to improve survival and reduce therapy-related toxicity.
Early studies showed that anti-CD33 constructs containing  particle-emitting iodine-131 or yttrium-90 could eliminate large leukemic burdens but resulted in prolonged myelosuppression requiring HCT. 4, 5 The unique physical and radiobiological properties of -particles may provide more efficient tumor cell killing and reduce the nonspecific cytotoxic effects seen with -emitters. The -particles have a shorter range (50-80 µm compared to 800-10,000 µm of -particles) and a higher linear energy transfer (LET) (100 keV/µm compared to 0.2 keV/µm of -particles). 6 As few as one or two -particles can kill a target cell. Therefore, the potential for more efficient and specific antitumor effects with less damage to surrounding normal tissues makes -particle immunotherapy an attractive approach for the treatment of cytoreduced or minimal disease. Lintuzumab (HuM195) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. It is also found on committed myelomonocytic and erythroid progenitors but not on pluripotent stem cells, granulocytes or nonhematopoietic tissues. 7, 8 Lintuzumab induces antibody-dependent cell-mediated cytotoxicity and can fix human complement in vitro. 9 Previous studies demonstrated that lintuzumab can target leukemia cells in patients without immunogenicity, 10 eliminate minimal residual disease in acute promyelocytic leukemia, 11 and produce occasional remissions in AML. [12] [13] [14] at 440 keV, thirty, 1-minute images beginning at the start of each injection followed by ten, 3-minute images were collected. 18 No significant extramedullary toxicities were seen. Grade I and II liver function abnormalities were seen in four patients (22%). The onset was typically 5 to 14 days following treatment, and these abnormalities resolved within 3 to 14 days. All 17 evaluable patients developed myelosuppression with a median time to recovery of 22 days (range: 12-41 days). Nearly all the 213 Bi-lintuzumab rapidly localized to and was retained in areas of leukemic involvement, including the bone marrow, liver and spleen. Despite avidity for free bismuth, the kidneys were not visualized. There was no significant catabolism or clearance of the drug, confirming the stability of the construct. The mean absorbed dose per amount of injected activity to the marrow, and therefore to CD33 + target cells, was 9.8 mSv/ MBq (range: 2.6-29.4 mSv/MBq). Absorbed dose ratios between these sites and the whole body were 1,000-fold greater than those seen with -emitting constructs in this antigen system and patient population. Blood and plasma antibody concentrations displayed typical  distributions over the first 20 to 40 minutes, followed by slower  clearance over the remaining 3 hours of sample collection.
17
Fourteen (93%) of 15 evaluable patients had reductions in circulating blasts, and 14 (78%) of 18 patients had reductions in the percentage of bone marrow blasts (Fig. 1) . No patients achieved CR, likely due to large tumor burdens in heavily pretreated patients and to the relatively low specific activities (329-766 MBq/mg) of 213 Bi-lintuzumab.
Nevertheless, this study demonstrated the safety, feasibility and antileukemic effects of 213 Bi-lintuzumab and was the first proof-of-concept for systemic targeted -particle immunotherapy in humans.

Sequential Cytarabine and 213 Bi-Lintuzumab
It may be hypothesized that a 1-2 log reduction in tumor burden could increase the number of 213 Bi atoms delivered to leukemia cells and produce remissions. To determine the effects of 213 Bi-lintuzumab against cytoreduced disease, the authors conducted a phase I/II trial in which patients first received a nonremittive dose of cytarabine to decrease the leukemic burden. 19 Thirty-one patients with newly diagnosed (n = 13) or relapsed/refractory (n = 18) AML were treated. Patients received cytarabine at a dose of 200 mg/m 2 daily by intravenous continuous infusion for 5 days. Four patients (one at each dose level) underwent detailed biodistribution and pharmacokinetic studies. In contrast to the results seen in the initial phase I trial where 213 Bilintuzumab was given as a single agent, 15 cardiac blood pooling was seen after the last injection in one patient treated with 27.5 MBq/kg, indicating saturation of CD33 antigen sites within the bone marrow, liver and spleen. Moreover, reduced bone marrow uptake of 213 Bi-lintuzumab was seen after multiple injections in all four patients, indicating saturation of antigen sites after partial cytoreduction with cytarabine. Although a relatively small group of heterogeneous patients were included in this trial, it showed that targeted -particle immunotherapy can be effective at reducing low-volume disease.
Actinium-225-Lintuzumab: A Targeted Alpha-Particle Nanogenerator
Preclinical Studies
The major obstacles to the widespread use of 213 Bi are its short half-life and the requirement of an on-site 225 Ac/ 213 Bi-generator. Therefore, the author developed a second generation construct in which the isotope generator is directly conjugated to a tumor-specific antibody. In this strategy, 225 Ac (t½ = 10 days) can serve as an in vivo generator of four -particles at or within a cancer cell. The macrocyclic ligand 1,4,7,10-tetraazacyclododecane tetraacetic acid (DOTA) and its derivatives have been used for labeling of antibodies with 225 Ac. A two-step procedure was developed in which 225 Ac is first conjugated to DOTA-SCN followed by labeling of this construct to antibody.
225
Ac-labeled tumor-specific antibodies can kill multiple cell lines in vitro with LD 50 values 1,000 to 10,000 times less than those of analogous 213 Bi constructs. These findings led to in vivo studies in nude mice bearing human prostate carcinoma and lymphoma xenografts. Single nanocurie doses of 225 Ac-labeled tumor-specific antibodies significantly improved survival over controls and cured a substantial fraction of animals.
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Phase I Study of 225 Ac-Lintuzumab
Based on the activity of 225 Ac-containing radioimmunoconjugates in the animal models, we conducted a phase I trial of 225 Ac-lintuzumab in advanced AML. 22 Eighteen patients with relapsed (n = 11) or refractory (n = 7) AML were treated with a single infusion of 225 Ac-lintuzumab at doses of 18.5 (n = 3), 37 (n = 4), 74 (n = 3), 111 (n = 6) or 148 (n = 2) kBq/kg. Dose-limiting toxicities including myelosuppression lasting more than 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients receiving 111and 148 kBq/kg occurred. The MTD was determined to be 111 kBq/kg. As expected myelosuppression was the most common toxicity. Median time to resolution of grade IV leukopenia was 27 days (range: 0-71 days). Significant extramedullary toxicities were limited to transient grade III liver function abnormalities in three patients. We analyzed plasma pharmacokinetics by gamma counting at energy windows for two daughters of 225 Ac, francium-221 ( 221 Fr) and 213 Bi. Two-phase elimination kinetics was seen with mean plasma t½- and t½- of 1.9 and 38 hours, respectively, similar to other lintuzumab constructs containing long-lived radionuclides. This is in contrast to 213 Bi-lintuzumab, where the half-life is determined primarily by the short-lived radionuclide. Peripheral blasts were eliminated in 10 of 16 evaluable patients (63%), but only at doses of >37 kBq/kg. Bone marrow blast reductions were seen in 10 of 15 evaluable patients (67%) at 4 weeks, including eight patients (53%) who had blast reductions of more than 50%. Three patients receiving 37, 111 and 148 kBq/kg respectively achieved marrow blasts of 5% or less.
SUMMARY
Systemically administered targeted -particle immunotherapy is feasible and has significant antitumor activity. The shorter range and higher linear energy transfer of -particles compared with -particles may allow for more efficient and selective killing of individual tumor cells. These physical properties suggest that radioimmunotherapy with -emitters may be best suited for the treatment of smallvolume disease, as borne out in these clinical trials. Although reductions in leukemic blasts were seen when both 213 Biand 225 Ac-lintuzmab were given as single agents in phase I trials, remissions were only seen after effective cytoreduction. The use of
